13-Feb-2024
Amplia Therapeutics moves to next phase of pancreatic cancer treatment trial
31-Aug-2022
Amplia Therapeutics receives $1.8 million R&D refund for cancer inhibitor studies
3-Aug-2022
Amplia Therapeutics achieves critical clinical milestone for lead cancer therapy
3-Oct-2021
Amplia Therapeutics says Garvan paper has increased its confidence in upcoming Phase 2 trial
28-Sep-2021
Amplia Therapeutics and Patrys outline unique cancer drugs at Proactive Lifesciences Webinar
26-Jul-2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
26-Jul-2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
21-Jul-2021
Amplia Therapeutics returns successful phase one trial results
19-Jul-2021
Garvan's June Seminar: The Power of Personalised Medicine
30-Jun-2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
28-Jun-2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
2-Jun-2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
18-Mar-2021
Amplia Therapeutics (ASX:ATX) signs agreement with Garvan Institute
17-Mar-2021
Amplia Therapeutics (ASX:ATX) completes single-dose study of AMP945
14-Oct-2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone